Umoja's technology can be used to reengineer a patient's own immune system to attack and destroy both hematologic and solid organ-based tumors. The platform incorporates the VivoVec delivery platform to generate cancer fighting cells in vivo, refractory acute cellular rejection (RACR)/chimeric antigen receptor (CAR) payload architecture (VivoCAR T cells that can be controlled by the RACR/CAR system), and the TumorTag platform to direct CAR T cells to tumors.

The series A financing, backed by life science investors MPM Captial, DCVC Bio, and Qiming Venture Partners USA, will enable Umoja to advance its platform and therapeutic programs to early clinical development.